NTC
UBX

NF Trinity Capital’s Unity Biotechnology UBX Stock Holding History

NF Trinity Capital’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-60,806
Closed -$9.9M – 54
2018
Q3 		$9.9M Hold
60,806
– – 1.31% 20
2018
Q2 		$9.16M Buy
+60,806
New +$8.89M 1.25% 17

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PIM
Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return

NF Trinity Capital's UBX Position: Q4 2018 in Review

NF Trinity Capital sold out of Unity Biotechnology (UBX) in Q4 2018, closing a stake of 60,806 shares — an estimated $9.9M sold.

NF Trinity Capital first reported a position in UBX in Q2 2018 and held it in 2 quarters. The position peaked at $9.9M in Q3 2018. 55 funds tracked by Wall St. Rank hold UBX as of Q4 2018.

  • NF Trinity Capital reported no remaining Unity Biotechnology position as of Q4 2018 after selling out during the quarter.
  • NF Trinity Capital sold 60,806 Unity Biotechnology shares in Q4 2018, an estimated $9.9M.
  • NF Trinity Capital first reported a position in Unity Biotechnology in Q2 2018 and held it in 2 quarters.
  • NF Trinity Capital's Unity Biotechnology position peaked at $9.9M in Q3 2018.
  • 55 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2018.

Based on NF Trinity Capital's 13F filing for Q4 2018, filed 31 Jan 2019.